Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Inversion recovery

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Inversion recovery. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2018-002130-20 Sponsor Protocol Number: 1.4 Start Date*: 2020-02-07
    Sponsor Name:Norfolk and Norwich University Hospitals NHS Foundation Trust
    Full Title: Research on Efficacy of Teriparatide use in the Return of recruits to Normal duty.
    Medical condition: Healthy individuals with stress fractures.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022117 - Injury, poisoning and procedural complications 10042212 Stress fracture PT
    20.1 10022117 - Injury, poisoning and procedural complications 10042212 Stress fracture PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-005109-19 Sponsor Protocol Number: ATTICUS Start Date*: 2015-11-10
    Sponsor Name:University Hospital Tuebingen
    Full Title: Apixaban for treatment of embolic stroke of undetermined source
    Medical condition: Patients with embolic stroke of undetermined source and at least on risk factor for cardiac embolism
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004861-29 Sponsor Protocol Number: Modic03 Start Date*: 2018-05-16
    Sponsor Name:FOU, Nevroklinikken, Oslo University Hospital -Ullevål
    Full Title: BackToBasic: The effect of Infliximab in patients with chronic low back pain and Modic changes. A randomized, double blind, placebo-controlled, multicenter trial
    Medical condition: Non-specific chronic low back pain of more than 6 months duration. We will only investigate those who have vertebral end-plate chanages(Modic changes) on MRI.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10008837 Chronic back pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004787-62 Sponsor Protocol Number: DUS Start Date*: 2014-11-26
    Sponsor Name:SOD Anestesia e Terapia Intensiva, DAI Oncologia, AOU Careggi, Firenze
    Full Title: Evaluation of muscle function recovery after deep neuromuscular blockade by acceleromyography of the adductor pollicis or diaphragmatic echography: comparison between sugammadex and neostigmine
    Medical condition: Muscle function recovery post neuromuscoular blockade
    Disease: Version SOC Term Classification Code Term Level
    19.1 10042613 - Surgical and medical procedures 10057286 Neuromuscular blockade reversal PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005052-25 Sponsor Protocol Number: AOP00101 Start Date*: 2015-06-29
    Sponsor Name:AZIENDA OSPEDALIERA DI PADOVA
    Full Title: Total versus corrected body weight for dosage of sugammadex in morbidly obese patients.
    Medical condition: Reversal of rocuronium-induced neuromuscular blockade
    Disease: Version SOC Term Classification Code Term Level
    18.0 10042613 - Surgical and medical procedures 10057286 Neuromuscular blockade reversal PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004704-34 Sponsor Protocol Number: RECIR Start Date*: 2021-03-16
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Recovery from deep neuromuscular blockade using different sugammadex doses in elderly patients undergoing laparoscopic robot-assisted prostatectomy: a prospective, randomized, double-blind clinical...
    Medical condition: Deep neuromuscular block in patients undergoing RALP under general anaesthesia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10057286 Neuromuscular blockade reversal PT
    Population Age: Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002636-25 Sponsor Protocol Number: RG_13-013NS Start Date*: 2013-09-11
    Sponsor Name:University of Birmingham
    Full Title: A Randomised Multicentre Open Label Blinded End Point Trial to Compare the Effects of Spironolactone to Chlortalidone on Left Ventricular Mass and Arterial Stiffness in Stage 3 Chronic Kidney Disease
    Medical condition: The condition under investigation is the disease changes that occur in patients with mild kidney disease that cause them to have a high rate of diseases such as heart failure, rhythm disturbance an...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001883-31 Sponsor Protocol Number: CARMRUSMIAMBULANCE20190823 Start Date*: 2020-02-25
    Sponsor Name:VU Univesity Medical Center (VUmc)
    Full Title: Microvascular Recovery using contrast Ultrasound in ST-elevation Myocardial Infarction in the ambulance (MRUSMI-Ambulance)
    Medical condition: ST elevation myocardial infarction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001965-17 Sponsor Protocol Number: AITT2013/5 Start Date*: 2013-09-26
    Sponsor Name:Debreceni Egyetem Orvos- és Egészségtudományi Centrum Aneszteziológiai és Intenzív Terápiás Tanszék
    Full Title: Incidence of postoperative residual neuromuscular blockade following the administration of rocuronium: A randomized placebo controlled study.
    Medical condition: The effect of sugammadex and neostigmin on postoperative residual neuromuscular blockade will be investigated, therefore the patients suffering from various conditions undergoing surgery in general...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10042613 - Surgical and medical procedures 10057286 Neuromuscular blockade reversal PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002937-31 Sponsor Protocol Number: MA30143 Start Date*: 2017-09-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis
    Medical condition: Relapsing remitting multiple sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    20.1 10029205 - Nervous system disorders 10039720 Sclerosis multiple LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed) AT (Completed) DK (Completed) DE (Completed) PT (Completed) BE (Completed) HU (Completed) PL (Completed) SK (Completed) ES (Ongoing) BG (Completed) SI (Completed) NL (Completed) GB (GB - no longer in EU/EEA) FR (Ongoing) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002437-39 Sponsor Protocol Number: SPI-103 Start Date*: 2004-12-21
    Sponsor Name:Daiichi Asubio Pharmaceuticals Inc.
    Full Title: A Phase IIb Randomized, Double-Blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan)Administered for 72 Hours by Continuo...
    Medical condition: Treatment of acute stroke.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002329-27 Sponsor Protocol Number: ETLAS-2 Start Date*: 2020-12-10
    Sponsor Name:Herlev Gentofte Hospital
    Full Title: Improving cerebral blood flow and cognition in patient with cerebral small vessel disease. The ETLAS-2 Trial.
    Medical condition: Cerebral small vessel disease and stroke.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10070879 Cerebral small vessel ischemic disease LLT
    22.1 10029205 - Nervous system disorders 10076994 Lacunar stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017085-22 Sponsor Protocol Number: SIMAR Start Date*: 2010-04-27
    Sponsor Name:Technische Universität München
    Full Title: Sugammadex improves muscle function after standard neuromuscular recovery (SIMAR) [Verbesserung der Muskelfunktion durch Sugammadex nach normaler neuromuskulärer Erholung]
    Medical condition: This study wants to test if sugammadex is able to improve postoperative muscle weakness/function and subjective well-being even after complete spontaneous recovery to TOF 0.9 of a rocuronium-induce...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10029315 Neuromuscular blockade PT
    12.0 10057286 Neuromuscular blockade reversal PT
    12.1 10036278 Postoperative complications NOS LLT
    12.1 10052617 Postoperative care LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001088-26 Sponsor Protocol Number: MN42928 Start Date*: 2021-12-21
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: SAKURABONSAI: CLINICAL, IMAGING AND BIOMARKER OPEN-LABEL STUDY IN NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) WITH SATRALIZUMAB AS AN INTERVENTION
    Medical condition: Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10077875 Neuromyelitis optica spectrum disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) FR (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004061-41 Sponsor Protocol Number: 101-MS-321 Start Date*: 2006-06-01
    Sponsor Name:BIOGEN IDEC LTD
    Full Title: An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o...
    Medical condition: Multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Prematurely Ended) FI (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) HU (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-005906-32 Sponsor Protocol Number: WAKE-UP Start Date*: 2012-09-24
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial
    Medical condition: Patients with acute ischemic stroke proven by MRI and unknown time from symptom onset which otherwise fulfil the approval criteria for intravenous thrombolysis in acute stroke
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) GB (Completed) DK (Completed) ES (Completed) NL (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000401-50 Sponsor Protocol Number: CT-PED-2010-01 Start Date*: 2011-08-09
    Sponsor Name:Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
    Full Title: Efficacy and safety of reversal with Sugammadex (BRIDION®) from deep Neuromuscular Blockade induced by rocuronium in children
    Medical condition: Neuromuscular Blockade induced by Rocuronium
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10057286 Neuromuscular blockade reversal PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001514-15 Sponsor Protocol Number: 101SK201 Start Date*: 2013-11-26
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) on Reducing Infarct Volume in Acute Ischem...
    Medical condition: Acute Ischemic Stroke
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-004886-29 Sponsor Protocol Number: MN39158 Start Date*: 2018-05-22
    Sponsor Name:Roche Farma SA (Soc unipersonal) que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche Ltd
    Full Title: A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSO...
    Medical condition: Multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10039720 Sclerosis multiple LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) EE (Completed) IE (Completed) CZ (Completed) FR (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) FI (Completed) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) SI (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) SK (Trial now transitioned) BG (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000693-11 Sponsor Protocol Number: MK-8616-169 Start Date*: 2019-08-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 4 Double-blinded, Randomized, Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade ...
    Medical condition: Neuromuscular Blockade reversal
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10057286 Neuromuscular blockade reversal PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) DK (Completed) FI (Completed) HU (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 17:16:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA